SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ruilope Luis M)
 

Sökning: WFRF:(Ruilope Luis M) > Design and Baseline...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004008naa a2200553 4500
001oai:DiVA.org:uu-409542
003SwePub
008200423s2019 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:142370620
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4095422 URI
0247 a https://doi.org/10.1159/0005037132 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1423706202 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Bakris, George L4 aut
2451 0a Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
264 c 2019-10-25
264 1b S. Karger AG,c 2019
338 a print2 rdacarrier
500 a UU-författare ingår i gruppen: FIDELIO-DKD study investigators
520 a BACKGROUND: Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet.METHODS: The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease -(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25-<75 mL/min/1.73 m2 and albuminuria (urinary albumin-to-creatinine ratio ≥30-≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death.CONCLUSION: FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653 a Aldosterone
653 a Clinical
653 a Diabetes
653 a Kidney
653 a Mineralocorticoid
653 a Outcomes
7001 a Agarwal, Rajiv4 aut
7001 a Anker, Stefan D4 aut
7001 a Pitt, Bertram4 aut
7001 a Ruilope, Luis M4 aut
7001 a Nowack, Christina4 aut
7001 a Kolkhof, Peter4 aut
7001 a Ferreira, Anna C4 aut
7001 a Schloemer, Patrick4 aut
7001 a Filippatos, Gerasimos4 aut
7001 a Soveri, Inga,d 1978-u Uppsala universitet,Institutionen för medicinska vetenskaper4 ctb
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t American Journal of Nephrologyd : S. Karger AGg 50:5, s. 333-344q 50:5<333-344x 0250-8095x 1421-9670
8564 u https://doi.org/10.1159/000503713y Fulltext
8564 u https://www.karger.com/Article/Pdf/503713
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-409542
8564 8u https://doi.org/10.1159/000503713
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:142370620

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy